SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company" or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), pending final resolution of the arbitration proceedings commenced by the Company and by Novo Nordisk A/S ("Novo Nordisk"). While the Company is disappointed with the decision to maintain the injunction, the Court of Appeal's judgment expressly makes clear that the substantive issues raised by Novo Nordisk must be determined by the arbitral tribunal. Currently, the arbitration proceedings commenced by each party are still ongoing.
1. No Finding of Fraud or Dishonesty by Court of Appeal
Section 12A of Singapore's International Arbitration Act empowers the Singapore court to grant temporary injunctions to preserve the status quo whilst a dispute is being resolved in ongoing arbitration proceedings. This does not involve a trial of the underlying merits.
